Department of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology Suzhou Medical College of Soochow University Suzhou China.
Suzhou Industrial Park Centers for Disease Control and Prevention Suzhou China.
J Am Heart Assoc. 2024 Oct;13(19):e035075. doi: 10.1161/JAHA.123.035075. Epub 2024 Sep 18.
Corin plays important roles in the regulation of blood volume and pressure and cardiac function by activating natriuretic peptide pathway, exerting multiple cardioprotective effects. But the impacts of soluble corin on clinical outcomes after ischemic stroke are unclear. We aimed to investigate the associations between serum soluble corin and long-term clinical outcomes after acute ischemic stroke.
We measured the concentrations of serum soluble corin in 3162 participants (2010 men and 1152 women) from the China Antihypertensive Trial in Acute Ischemic Stroke. The clinical outcomes were recurrent stroke, cardiovascular events, all-cause mortality, and unfavorable functional outcome within 24 months after stroke. Risk reclassification for study clinical outcomes of models with soluble corin were evaluated. Serum soluble corin was inversely associated with recurrent stroke, cardiovascular events, and unfavorable functional outcome after ischemic stroke. After adjusting for multiple covariates, each additional SD of log-corin was associated with a 21% (95% CI, 11-30), 16% (95% CI, 6-26), and 12% (95% CI, 3-21) decreased risk for recurrent stroke, cardiovascular events, and unfavorable functional outcome, respectively. Furthermore, the addition of soluble corin to the basic model with conventional risk factors significantly improved risk discrimination for recurrent stroke, cardiovascular events, and the composite outcome of all-cause mortality and cardiovascular events, as shown by C-statistics (all <0.05).
Serum soluble corin was associated with decreased risks of long-term clinical outcomes, and may be a promising prognostic biomarker for risk stratification in patients with acute ischemic stroke.
Corin 通过激活利钠肽途径在调节血容量和血压以及心功能方面发挥重要作用，具有多种心脏保护作用。但是可溶性 Corin 对缺血性卒中后临床结局的影响尚不清楚。我们旨在研究血清可溶性 Corin 与急性缺血性卒中后长期临床结局之间的关系。
我们测量了来自中国急性缺血性卒中降压试验（China Antihypertensive Trial in Acute Ischemic Stroke）的 3162 名参与者（2010 名男性和 1152 名女性）血清可溶性 Corin 的浓度。临床结局为卒中后 24 个月内的复发性卒中、心血管事件、全因死亡率和不良功能结局。评估了可溶性 Corin 模型对研究临床结局的风险重新分类。血清可溶性 Corin 与缺血性卒中后复发性卒中、心血管事件和不良功能结局呈负相关。在调整了多个协变量后，log-Corin 的每增加一个标准差，与复发性卒中、心血管事件和不良功能结局的风险降低 21%（95%CI，11-30）、16%（95%CI，6-26）和 12%（95%CI，3-21）分别相关。此外，将可溶性 Corin 添加到具有常规危险因素的基本模型中，显著提高了复发性卒中、心血管事件和全因死亡率和心血管事件复合结局的风险区分能力，表现为 C 统计量（均<0.05）。
血清可溶性 Corin 与长期临床结局的风险降低相关，可能是急性缺血性卒中患者风险分层的有前途的预后生物标志物。
